Position in ABSI
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$232,560
-$37,984 QoQ
Shares Held
77,520
0.0% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ABSI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026KING LUTHER CAPITAL MANAGEMENT CORP holds $9,019,114 across 6 Biotechnology names. ABSI ranks #5 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
66,584 | $4,303,323 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
53,725 | $3,368,557 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
948 | $732,462 | |
| 4 | MNKD |
Mannkind Corp
|
138,605 | $339,582 | |
| 5 | ABSI |
Absci Corp
This page
|
77,520 | $232,560 | |
| 6 | RANI |
Rani Therapeutics Holdings, Inc.
|
58,000 | $42,630 |
All Filings in ABSI
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $232,560 | 77,520 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $270,544 | 77,520 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $235,660 | 77,520 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $199,226 | 77,520 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $194,575 | 77,520 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $203,102 | 77,520 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $296,126 | 77,520 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||